A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2000 Feb 19

PMID 10681319

Citations 33

Authors

K Hertogs

S Bloor

V De Vroey

C Van Den Eynde

P Dehertogh

A van Cauwenberge

M Sturmer

T Alcorn

S Wegner

M Van Houtte

V Miller

B A Larder

Affiliations

Soon will be listed here.

Abstract

We describe a new human immunodeficiency virus type 1 (HIV-1) mutational pattern associated with phenotypic resistance to lamivudine (3TC) in the absence of the characteristic replacement of methionine by valine at position 184 (M184V) of reverse transcriptase. Combined genotypic and phenotypic analyses of clinical isolates revealed the presence of moderate levels of phenotypic resistance (between 4- and 50-fold) to 3TC in a subset of isolates that did not harbor the M184V mutation. Mutational cluster analysis and comparison with the phenotypic data revealed a significant correlation between moderate phenotypic 3TC resistance and an increased incidence of replacement of glutamic acid by aspartic acid or alanine and of valine by isoleucine at residues 44 and 118 of reverse transcriptase, respectively. This occurred predominantly in those isolates harboring zidovudine resistance-associated mutations (41L, 215Y). The requirement of the combination of mutations 41L and 215Y with mutations 44D and 44A and/or 118I for phenotypic 3TC resistance was confirmed by site-directed mutagenesis experiments. These data support the assumption that HIV-1 may have access to several different genetic pathways to escape drug pressure or that the increase in the frequency of particular mutations may affect susceptibility to drugs that have never been part of a particular regimen.

Citing Articles

A Qualitative Study on the Burden of Nonadherence to Antiretroviral Therapy Among People Living With HIV/AIDS in Jharkhand, India.

Kumar M, Priya N, Kumar A, Kujur A, Kachhap A, Sagar V Cureus. 2024; 16(11):e73636.

PMID: 39677267 PMC: 11645451. DOI: 10.7759/cureus.73636.

Study protocol: Strengthening understanding of effective adherence strategies for first-line and second-line antiretroviral therapy (ART) in selected rural and urban communities in South Africa.

Gumede S, de Wit J, Venter W, Lalla-Edward S PLoS One. 2021; 16(12):e0261107.

PMID: 34932588 PMC: 8691643. DOI: 10.1371/journal.pone.0261107.

Understanding adherence in virally suppressed and unsuppressed human immunodeficiency virus-positive urban patients on second-line antiretroviral treatment.

Gumede S, Venter W, Lalla-Edward S South Afr J HIV Med. 2020; 21(1):1107.

PMID: 32934834 PMC: 7479367. DOI: 10.4102/sajhivmed.v21i1.1107.

HIV Reverse Transcriptase and Protease Genes Variability Can Be a Biomarker Associated with HIV and Hepatitis B or C Coinfection.

Cantao N, de Almeida L, Wolf I, Oliveira Almeida R, Alves de Almeida Cruz A, Nunes C Sci Rep. 2018; 8(1):8280.

PMID: 29844604 PMC: 5974300. DOI: 10.1038/s41598-018-26675-z.

Optimizing ART adherence: update for HIV treatment and prevention.

Robbins R, Spector A, Mellins C, Remien R Curr HIV/AIDS Rep. 2014; 11(4):423-33.

PMID: 25304006 PMC: 4268351. DOI: 10.1007/s11904-014-0229-5.

References

Boucher C, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg M . High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1993; 37(10):2231-4. PMC: 192256. DOI: 10.1128/AAC.37.10.2231. View

Tisdale M, Kemp S, Parry N, Larder B . Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993; 90(12):5653-6. PMC: 46779. DOI: 10.1073/pnas.90.12.5653. View

Kellam P, Larder B . Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother. 1994; 38(1):23-30. PMC: 284391. DOI: 10.1128/AAC.38.1.23. View

Gu Z, Gao Q, Fang H, Salomon H, Parniak M, Goldberg E . Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother. 1994; 38(2):275-81. PMC: 284440. DOI: 10.1128/AAC.38.2.275. View

Gu Z, Fletcher R, Arts E, Wainberg M, Parniak M . The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J Biol Chem. 1994; 269(45):28118-22. View

Shirasaka T, Kavlick M, Ueno T, Gao W, Kojima E, Alcaide M . Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A. 1995; 92(6):2398-402. PMC: 42491. DOI: 10.1073/pnas.92.6.2398. View

Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P . Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995; 171(6):1411-9. DOI: 10.1093/infdis/171.6.1411. View

Shafer R, Iversen A, Winters M, Aguiniga E, Katzenstein D, Merigan T . Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis. 1995; 172(1):70-8. DOI: 10.1093/infdis/172.1.70. View

Larder B, Kemp S, Harrigan P . Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995; 269(5224):696-9. DOI: 10.1126/science.7542804. View

10.

Iversen A, Shafer R, Wehrly K, Winters M, Mullins J, Chesebro B . Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol. 1996; 70(2):1086-90. PMC: 189915. DOI: 10.1128/JVI.70.2.1086-1090.1996. View

11.

Jacobsen H, Hanggi M, Ott M, Duncan I, Owen S, Andreoni M . In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis. 1996; 173(6):1379-87. DOI: 10.1093/infdis/173.6.1379. View

12.

Harrigan P, Kinghorn I, Bloor S, Kemp S, Najera I, Kohli A . Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol. 1996; 70(9):5930-4. PMC: 190612. DOI: 10.1128/JVI.70.9.5930-5934.1996. View

13.

Schmit J, Ruiz L, Clotet B, Raventos A, Tor J, Leonard J . Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS. 1996; 10(9):995-9. DOI: 10.1097/00002030-199610090-00010. View

14.

Hertogs K, De Bethune M, Miller V, Ivens T, Schel P, van Cauwenberge A . A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother. 1998; 42(2):269-76. PMC: 105399. DOI: 10.1128/AAC.42.2.269. View

15.

Montaner J, Reiss P, Cooper D, Vella S, Harris M, Conway B . A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998; 279(12):930-7. DOI: 10.1001/jama.279.12.930. View

16.

Drusano G, Bilello J, Stein D, Nessly M, Meibohm A, Emini E . Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J Infect Dis. 1998; 178(2):360-7. DOI: 10.1086/515631. View

17.

Schmit J, Van Laethem K, Ruiz L, Hermans P, Sprecher S, Sonnerborg A . Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS. 1998; 12(15):2007-15. DOI: 10.1097/00002030-199815000-00012. View

18.

Winters M, Coolley K, Girard Y, Levee D, Hamdan H, Shafer R . A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest. 1998; 102(10):1769-75. PMC: 509125. DOI: 10.1172/JCI4948. View

19.

Huang H, Chopra R, Verdine G, Harrison S . Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science. 1998; 282(5394):1669-75. DOI: 10.1126/science.282.5394.1669. View

20.

Miller V, De Bethune M, Kober A, Sturmer M, Hertogs K, Pauwels R . Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother. 1998; 42(12):3123-9. PMC: 106010. DOI: 10.1128/AAC.42.12.3123. View